Nucleic Acids Core Facility (David Lee, Ph.D., Faculty Director; Qing Yang, Ph.D., Facility Supervisor) The goal of the Nucleic Acids Core Facility (NACF) is to provide LCCC investigators with rapid access to high-quality oligonucleotides at the lowest practical cost. The facility provides investigators. with oligonucleotides for use in various applications, including DNA sequencing, PCR, cDNA synthesis, Northern/Southern Blots, in vitro mutagenesis, anti-sense inhibition of gene expression, and studies of DNA-protein interaction. The NACF also offers a wide range of custom synthesis options, including RNA oligomers, phosphorothioate oligomers, degenerate oligos, and oligo labeling with biotin, fluorescein, and many other compound. Over the past five years, the facility has implemented a number of measures that have improved services and reduced prices, including quality control measures, an on-line ordering system, purification of oligos, more efficient synthesis chemistries, a drying system, and a freezer program. These changes have resulted in several reductions in the price per base of 40 nmole scale synthesis, from $1.60 to its current level of $0.90, with plans for a further reduction to $0.80 per base in 1999 with the arrival of a new ABI 3948 DNA synthesizer. A continued high level of use by 87 peer-reviewed Cancer Center members accounted for over 83% of the facility's use in 1997-1998. CCSG support of $84,732 is requested, 89% of which will be used to support the facility's service-oriented personnel. This amount represents 26% of the facility's total budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-25
Application #
6398591
Study Section
Project Start
2000-05-01
Project End
2000-11-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Gralinski, Lisa E; Sheahan, Timothy P; Morrison, Thomas E et al. (2018) Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. MBio 9:
Au, Kin Man; Tripathy, Ashutosh; Lin, Carolina Pe-I et al. (2018) Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano 12:1544-1563
Mirlekar, Bhalchandra; Michaud, Daniel; Searcy, Ryan et al. (2018) IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. Cancer Immunol Res 6:1014-1024

Showing the most recent 10 out of 1525 publications